Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Hepatic encephalopathy (maintenance treatment) - rifaximin: evaluation report

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the manufacturer - Norgine

03a - NICE request to the manufacturer for clarfication on their submission

03b - Manufacturer clarification response

03bi - Appendix A Updated Effectiveness Search

03bii - Appendix B Updated Cost effectiveness Search

03biii - Appendix C Updated HRQL Search

04 - Consultee submission - British Society of Gastroenterology

05a - Patient expert personal perspective - Andrew Langford

05b - Clinical expert declaration - Dr Sulleman Moreea

05c - Clinical expert personal perspective - Dr Debbie Shawcross

06a - Evidence Review Group report prepared by Peninsula Technology Assessment Group

06b - Evidence Review Group Report Erratum

06c - Evidence Review Group Report Addendum

07 - Manufacturer factual accuracy check